A Study of Cabergoline for the Treatment of Cocaine Dependence - 1

This study has been completed.
Sponsor:
Collaborator:
University of California, Los Angeles
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00033111
First received: April 5, 2002
Last updated: July 21, 2008
Last verified: July 2008
  Purpose

The purpose of this study is to assess cabergoline for the Treatment of Cocaine Dependence


Condition Intervention Phase
Cocaine-Related Disorders
Substance-Related Disorders
Drug: Cabergoline
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Phase 2, Double-Blind, Placebo Controlled Trial of Cabergoline for the Treatment of Cocaine Dependence

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • New Use
  • reduction of severity of cocaine dependence

Estimated Enrollment: 140
Study Start Date: June 2001
Study Completion Date: April 2004
Detailed Description:

To assess the efficacy and safety of cabergoline in reducing cocaine use in subjects with cocaine dependence. This is a DB, placebo-controlled, parallel group design study where subjects will receive either .5mg cabergoline or placebo for 12 weeks with a 4 week follow-up.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Must have a DSM-4 criteria for cocaine dependence; be seeking treatment for cocaine dependence; have the ability to understand and provide written informed consent; females of child-bearing potential using proper method of birth control.

Exclusion Criteria:

Additional criteria available during screening at the site.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00033111

Locations
United States, California
Torrance Clinic
Torrance, California, United States, 90502
United States, South Carolina
Medical University of South Carolina
Charleston, South Carolina, United States, 29425
Sponsors and Collaborators
University of California, Los Angeles
Investigators
Principal Investigator: Steve Shoptaw, Ph.D. Friends Research Institute, Inc.
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00033111     History of Changes
Obsolete Identifiers: NCT00024895
Other Study ID Numbers: NIDA-CTO-0007-1
Study First Received: April 5, 2002
Last Updated: July 21, 2008
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Cocaine-Related Disorders
Disease
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Pathologic Processes
Cabergoline
Anti-Dyskinesia Agents
Antineoplastic Agents
Antiparkinson Agents
Central Nervous System Agents
Dopamine Agents
Dopamine Agonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on October 22, 2014